AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06384560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks.
Study NCT06384560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX is a combination of systemic chemotherapy agents. FOLFIRINOX consists of oxaliplatin at a dose of 85 mg/m2, given as a 2-hour intravenous infusion, immediately followed by leucovorin at a dose of 400 mg/m2 given as a 2-hour intravenous infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute intravenous infusion through a Y-connector. This treatment is followed by a continuous intravenous infusion of 2400 mg/m2 5-FU over a 46-hour period every 2 weeks. (The FOLFIRINOX given in the trial is the modified scheme, whereby the fluorouracil bolus at a dose of 400 mg/m2 is omitted and the irinotecan dose reduced to 150 mg/m2).
Study NCT06384560 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on five non-consecutive days.
Study NCT06646289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Description: AAV5-hRKp.RPGR will be administered sub-retinally.
Study NCT06646289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention (Follow-Up assessment)
Description: Participants will not receive any intervention and will undergo follow-up assessment.
Study NCT04765722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
Study NCT04765722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
Study NCT06075537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose
Study NCT06244771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMC-376
Description: Oral Capsule
Study NCT06538142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation + Restoration with Self-cure Composite Resin
Description: 1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Application of photobiomodulation;~4. Relative isolation (lip bumper, cotton roll and aspirator);~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Cleaning with cotton and water;~7. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~8. Application of mild compressed air on adhesive for 3 seconds;~9. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~10. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~11. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months.
Study NCT06538142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Self-cure Composite Resin
Description: 1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Relative isolation (lip bumper, cotton roll and aspirator);~4. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~5. Cleaning with cotton and water;~6. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~7. Application of mild compressed air on adhesive for 3 seconds;~8. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~9. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~10. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months.
Study NCT06538142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin
Description: 1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment;~3. Relative isolation;~4. Application of photobiomodulation;~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Selective etching of enamel adjacent to demarcated opacities with 35% phosphoric acid for 20s;~7. Active application of universal adhesive (Ambar) on dentin and enamel for 20 seconds (repeat procedure);~8. Application of mild compressed air on adhesive for 5 seconds;~9. Photoactivation for 10s;~10. Restoration with Tetric N Ceram bulk-fill composite resin; with increments up to 4 mm, extending to demarcated opacities;~11. Photoactivation for 10 seconds;~12. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~13. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months.
Study NCT05641402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Text messages
Description: Text messages based on behaviour change techniques
Study NCT05634499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
Study NCT05408845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT05408845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05408845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05408845 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study NCT05408845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study NCT05657691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem™
Description: Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
Study NCT05657691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
Study NCT04893954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full Spine Radiography
Description: Full Spine Radiography
Study NCT04893954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumbar spine MRI
Description: Lumbar spine MRI
Study NCT06538857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard surgery
Description: The location and size of the tumor determine the type of surgery.
Study NCT06538857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery
Description: The location and size of the tumor determine the type of surgery.
Study NCT06538857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEB-01
Description: It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
Study NCT05304104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
Study NCT05304104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
Study NCT06225297 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention package
Description: Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
Study NCT06457685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Intravascular Lithotripsy (Pulse IVL)
Description: The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
Study NCT04775381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive a cholecalciferol supplementation added to a fruit juice.
Study NCT06179758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: icompanion app
Description: use of the icompanion app as a digital telemonitoring solution
Study NCT04499924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg given twice daily orally
Study NCT04499924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
Study NCT04499924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: 8 mg/kg will be administered IV on Days 1 and 15 of each cycle
Study NCT04499924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramucirumab
Description: 8 mg/kg will be administered IV on Days 1 and 15 of each cycle
Study NCT04499924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
Study NCT04499924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
Study NCT04499924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tucatinib placebo
Description: Given twice daily orally
Study NCT04499924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab placebo
Description: IV on Days 1 and 15 of each cycle
Study NCT04499924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trastuzumab placebo
Description: IV on Days 1 and 15 of each cycle
Study NCT06489197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab combined with albumin paclitaxel and cisplatin
Description: Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
Study NCT06485635 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study NCT06485635 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone
Study NCT05759754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM+ Routine Therapy
Description: The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued.
Study NCT05759754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Therapy
Description: Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
Study NCT04906226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-foot massage
Description: The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
Study NCT05113680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compassion focused group
Description: Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each
Study NCT05113680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: emotional competencies
Description: Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
Study NCT04824898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
Study NCT04824898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injectable plasma rich fibrin
Description: I- PRF is obtained by taking a blood sample from patients and then is centrifuged for three minutes at 3300 rpm, the I-PRF first will be in the form of liquid and then coagulate after few minutes from the injection
Study NCT05440708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet
Study NCT05440708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT05440708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous (IV) infusion
Study NCT05440708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous (IV) infusion
Study NCT05613036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)
Study NCT05613036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)
Study NCT05613036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: BI 907828
Study NCT05399537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prismocitrate 18
Description: Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
Study NCT05399537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrisMax System Version 3.x with calcium line accessory
Description: The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.
Study NCT05269667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab 120 mg
Description: Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
Study NCT05495269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101 ophthalmic solution, 2.0 %
Description: ophthalmic solution in a single use dropper vial
Study NCT05302375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPath*D
Description: Online pathway from screening to treatment for depression in cancer patients.
Study NCT05745246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-health training program
Description: 1. Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~2. A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~3. A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information.
Study NCT06500455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06500455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06500455 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FSRS
Study NCT06500455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06500455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06500455 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT05524922 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
Study NCT06144294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Hyperthermia
Description: The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
Study NCT06144294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
Study NCT04969094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
Study NCT04969094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Modality Balance Intervention (MMBI)
Description: Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
Study NCT04969094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Modality Balance Intervention (MMBI)
Description: Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
Study NCT06311682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab + TCS
Description: The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.